Evidence map›Paper›PMID 40704619›Full record

ArticleImmunity, inflammation and disease2025

APOBEC3C-Mediated NF-κB Activation Promotes Malignant Progression of Gliomas.

Chao Zhang, Tao Yang, Yuhang Tang, Dong Yu, Shiqiang Hou, Ning Lin, Qun Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chao ZhangDepartment of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.ORCID 0009-0007-6925-4569
Tao YangDepartment of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
Yuhang TangDepartment of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
Dong YuDepartment of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
Shiqiang HouDepartment of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
Ning LinDepartment of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
Qun LiHealth Examination Center, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.

Funding

This work was supported by the Scientific Research Foundation of the Education Department of Anhui Province (Grant No. 2024AH040093); Chuzhou Science and Technology Program (Grant No. 2024YF007); Scientific Research Project of Health Commission of Chuzhou (Grant No. CZWJ2024A001); and Postgraduate Innovation Research and Practice Program of Anhui Medical University (Grant No. YJS20240040).
6 · The paper itself

Abstract

objectiveTo analyze the clinicopathological features, immunological characteristics, and prognostic value of APOBEC3C in gliomas, and to verify the specific mechanism by which it mediates the malignant progression of gliomas.

methodsmRNA-seq data from 693 glioma patients in the CGGA database and 697 glioma patients in the TCGA were analyzed, respectively. In addition, single-cell sequencing data were obtained from the CGGA database. Bioinformatics methods were applied to reveal the possible mechanisms of APOBEC3C-mediated malignant progression of gliomas. Moreover, western blot, transwell, and cell-scratch assays were used to explore the potential mechanisms of APOBEC3C-mediated glioma invasion and migration.

resultsAPOBEC3C was enriched in malignant glioma subtypes and was a potential biomarker for mesenchymal subtypes in glioma patients. It was closely associated with glioma inflammation and immunity. Additionally, APOBEC3C is a potential independent prognostic factor for glioma, and inhibition of APOBEC3C expression can suppress the EMT process in glioma cells through the NF-κB signaling pathway.

conclusionAPOBEC3C is a potential biomarker for glioma patients. It is closely related to the clinicopathology of glioma and may be a potential immunotherapy target for glioma patients.

Indexed as

Brain NeoplasmsCytidine DeaminaseGliomaNF-kappa BBiomarkers, TumorCell Line, TumorCell MovementDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisSignal TransductionBiomarkers, TumorCytidine DeaminaseNF-kappa BAPOBEC3CgliomaNF‐κBprognosis

Identifiers

PMID40704619
PMCPMC12287792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.